Acute Kidney Injury Associated with Linagliptin
Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney i...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2016/5695641 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565147077443584 |
|---|---|
| author | Deepak K. Nandikanti Elvira O. Gosmanova Aidar R. Gosmanov |
| author_facet | Deepak K. Nandikanti Elvira O. Gosmanova Aidar R. Gosmanov |
| author_sort | Deepak K. Nandikanti |
| collection | DOAJ |
| description | Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney injury (AKI) in a patient with preexisting chronic kidney disease (CKD). We hypothesize that AKI was due to renal hypoperfusion from linagliptin-induced natriuresis and intravascular volume contraction in the setting of concomitant lisinopril use, which is known to impair autoregulation and potentiate hypotension-induced AKI. It may be prudent to exert caution and closely monitor kidney function when initiating linagliptin in combination with ACE-inhibitors in CKD patients. |
| format | Article |
| id | doaj-art-21116b383add42d2939e4ce6a393b13f |
| institution | Kabale University |
| issn | 2090-6501 2090-651X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Endocrinology |
| spelling | doaj-art-21116b383add42d2939e4ce6a393b13f2025-02-03T01:09:07ZengWileyCase Reports in Endocrinology2090-65012090-651X2016-01-01201610.1155/2016/56956415695641Acute Kidney Injury Associated with LinagliptinDeepak K. Nandikanti0Elvira O. Gosmanova1Aidar R. Gosmanov2Kidney Specialists of Southern Nevada, Las Vegas, NV 89106, USANephrology Section, Stratton VA Medical Center, Albany, NY 12208, USAEndocrinology Section, Stratton VA Medical Center, Albany, NY 12208, USALinagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney injury (AKI) in a patient with preexisting chronic kidney disease (CKD). We hypothesize that AKI was due to renal hypoperfusion from linagliptin-induced natriuresis and intravascular volume contraction in the setting of concomitant lisinopril use, which is known to impair autoregulation and potentiate hypotension-induced AKI. It may be prudent to exert caution and closely monitor kidney function when initiating linagliptin in combination with ACE-inhibitors in CKD patients.http://dx.doi.org/10.1155/2016/5695641 |
| spellingShingle | Deepak K. Nandikanti Elvira O. Gosmanova Aidar R. Gosmanov Acute Kidney Injury Associated with Linagliptin Case Reports in Endocrinology |
| title | Acute Kidney Injury Associated with Linagliptin |
| title_full | Acute Kidney Injury Associated with Linagliptin |
| title_fullStr | Acute Kidney Injury Associated with Linagliptin |
| title_full_unstemmed | Acute Kidney Injury Associated with Linagliptin |
| title_short | Acute Kidney Injury Associated with Linagliptin |
| title_sort | acute kidney injury associated with linagliptin |
| url | http://dx.doi.org/10.1155/2016/5695641 |
| work_keys_str_mv | AT deepakknandikanti acutekidneyinjuryassociatedwithlinagliptin AT elviraogosmanova acutekidneyinjuryassociatedwithlinagliptin AT aidarrgosmanov acutekidneyinjuryassociatedwithlinagliptin |